TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Short-Term Anti-plaque Effect of Cymenol Mouthwash Analysed Using Dentius Deep Plaque Software

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria were as follows:~* Systemically healthy volunteers~* Age between 20-45 years~* Presence of minimum of 24 permanent teeth~* No evidence of gingivitis or periodontitis (CPITN= 0)~* No presence of untreated caries at the start of the study.~Exclusion criteria were as follows:~* Smoker or ex-smoker~* Presence of dentures or orthodontic appliances~* Antibiotic treatment in the last 3 months or routine use of oral antiseptics

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants rinsed 10 ml of placebo mouthwash for a period of 60 seconds, three times a day with an interval of 7-9 hours in between, for 4 days (period 1)
- Cymenol (test) (Type: EXPERIMENTAL): Participants applied a 10 ml rinse of 0.1% cymenol mouthwash for a period of 60 seconds, three times a day with a 7-9 hour interval in between, for 4 days (period 1) and 4 days more (period 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~Diagnosis of rheumatoid arthritis (RA), according to the American College of Rheumatology/The European League Against Rheumatism (ACR/EULAR) 2010 Rheumatoid Arthritis Classification Criteria with \>=3 months disease duration.~Moderately to severely active RA defined as:~* At least 4 of 68 tender joints and 4 of 66 swollen joints at screening visit.~* High sensitivity C-Reactive Protein (hs-CRP) \>=4 mg/L or Erythrocyte Sedimentation Rate (ESR) \>=28 mm/hr at screening visit.~For the combination stratum:~Participants who had continuous treatment with non-biologic DMARDs other than MTX for at least 12 weeks prior to the randomization and on a stable dose for a minimum of 6 weeks prior to screening.~For the monotherapy stratum:~Participants who per investigator judgment were any of inappropriate, intolerant or inadequate to MTX treatment.~Exclusion criteria:~Participants \<20 years of age. Prior treatment with tumor necrosis factor (TNF) antagonists or any other RA-directed biologic agents without the appropriate off-drug period prior to screening.~Prior treatment with anti-interleukin-6 (anti-IL-6) or anti-interleukin-6 receptor (IL-6R) antagonist therapies, including but not limited to tocilizumab or sarilumab.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sarilumab 150 mg q2w + DMARDs (Type: EXPERIMENTAL): Participants received sarilumab 150 mg, subcutaneous (SC) injection, once every two weeks (q2w) along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
- Sarilumab 200 mg q2w + DMARDs (Type: EXPERIMENTAL): Participants received sarilumab 200 mg, SC injection, q2w along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
- Sarilumab 150 mg q2w (Type: EXPERIMENTAL): Participants received sarilumab 150 mg, SC injection, q2w for up to 52 weeks.
- Sarilumab 200 mg q2w (Type: EXPERIMENTAL): Participants received sarilumab 200 mg, SC injection, q2w for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hemosonics- VCU Cardiac Surgery Clinical Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is scheduled for cardiac surgery involving bypass circuit~* Subject is older than 18 years~* Subject is willing to participate and he/she has signed a consent form~Exclusion Criteria:~* Subject is unable to provide written informed consent~* Subject is incarcerated at the time of the study~* Subject is affected by any condition that, in the opinion of the surgical team, may pose additional risks~* Patients on emergency cases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Cardiac Surgery Patients (Type: None): Single cohort of 50 consecutive cardiac surgery patients undergoing cardiopulmonary bypass. The study compares output of two technologies for determination of point of care coagulation function: thromboelastography (TEG; current care option) and the new technology Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Panitumumab IRDye800 Optical Imaging Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck~* Patients diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Patients with recurrent disease or a new primary will be allowed.~* Planned standard of care surgery with curative intent for squamous cell carcinoma~* Age ≥ 19 years~* Have life expectancy of more than 12 weeks~* Karnofsky performance status of at least 70% or ECOG/Zubrod level 1~* Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results: Hemoglobin ≥ 9 gm/dL; White blood cell count \> 3000/mm3; Platelet count ≥ 100,000/mm3; Serum creatinine ≤ 1.5 times upper reference range~Exclusion Criteria~* Received an investigational drug within 30 days prior to first dose of panitumumab IRDye800~* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment~* History of infusion reactions monoclonal antibody therapies~* Pregnant or breastfeeding~* Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females)~* Magnesium or potassium lower than the normal institutional values~* Patients receiving Class IA (quinidine, procanamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.~* Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis~* TSH \> 13 micro International Units/mL

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panitumumab IRDye 800 (Type: EXPERIMENTAL): Patients will receive Panitumumab IRDye800 prior to their scheduled surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zambia Integrated Management of Malaria and Pneumonia Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 6 months and 5 years~* Present with history of fever or reported fever~* Present with cough or difficult breathing~Exclusion Criteria:~* Age below 6 months and above 5 years~* Presence of signs and symptoms of severe illness

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on rapid diagnostic test. For pneumonia, give one half tablet (250mg amoxicillin) for children weighing (5-9.9kg) and one tablet for children weighing (10-20kg) three times a day for five days.
- 2 (Type: ACTIVE_COMPARATOR): Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on clinical diagnosis. For pneumonia, refer to the nearest health facility

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients aged 18 years or older~2. Chronic AD that had been present for at least 2 years~Exclusion Criteria:~1. Prior treatment with Dupilumab~2. Hypersensitivity to corticosteroids or to any other ingredients contained by the TCS product used in the study~3. AD lesions located on face, flexural, and genital areas~4. Certain treatments and medical procedures, undertaken within a particular time frame prior to the baseline visit, preclude eligibility for participation in the study~5. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit~6. Treatment with an investigational drug within 8 weeks~7. Known history of human immunodeficiency virus (HIV) infection~8. Presence of certain laboratory abnormalities at the screening visit~9. History of certain opportunistic infections or certain clinical parasite infections~10. History of malignancy within 5 years before the baseline visit, with certain exceptions~11. Pregnant or breast-feeding women~12. Travel within 12 months of study start to areas endemic for parasitic infections, such as developing countries in Africa and the tropical and subtropical regions of Asia~13. History of alcohol or drug abuse within 2 years of the screening visit~14. Any medical or psychiatric condition which, in the opinion of the investigator or the sponsor's medical monitor, would place the patient at risk, interfere with participation in the study, or interfere with the interpretation of study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo QW (Type: EXPERIMENTAL): Placebo (for Dupilumab) once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent topical corticosteroid (TCS) for up to 28 days
- Dupilumab 300 mg QW (Type: EXPERIMENTAL): Dupilumab 300 mg once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent TCS for up to 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Administration of Low Dose Adrenaline During Surgery on Bleeding During Hip Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years.~* Scheduled for primary unilateral hip arthroplasty~* Able to give consent~Exclusion Criteria:~* Allergy towards adrenaline~* Current treatment with: ADP receptor inhibitors or Vitamin K antagonists (within 5 days), Factor Xa inhibitors or Thrombin inhibitors (within 1 day), heparin (excluding low molecular weight heparin for perioperative thromboprophylaxis).~* Current treatment with tricyclic antidepressants~* Use of MAO inhibitors (within previous 14 days) or COMT inhibitors (within 2 days).~* Acute coronary syndrome / myocardial infarction within the previous 6 months.~* not willing to accept blood transfusion~* Participation in other clinical trial within previous 30 days~* Women of childbearing age (without menopause for at least 12 months)~* Glaucoma~* Pheochromocytoma~* Low serum K+ (\< 3.0 mmol/L)~* Thyrotoxicosis~* Digoxin intoxication~* Alcohol og drug abuse (investigators judgement)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adrenaline (Type: EXPERIMENTAL): Intraoperative low-dose adrenaline infusion
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: Isotonic Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dysport® Adult Lower Limb Spasticity Follow-on Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of Dysport® Adult Lower Limb Spasticity Double Blind study Y-55-52120-140 (NCT01249404)~Exclusion Criteria:~* Fixed contractures in lower limb

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dysport® (Type: EXPERIMENTAL): Dysport® is injected into lower limbs across 4 cycles of treatment, a minimum of 12 weeks between 2 injections. Doses vary from 1000 U to 1500 U.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of LLLT and Ozone to Reduce Complications After Extraction of Impacted Lower Molar

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who had mandibular third molar, totally or partially impacted in the bone (Class II-III and position B, Pell and Gregory's classification), in need of surgical extraction, which were evaluated clinically and by radiological examination.~* Patients who were in age range between 18-40 years old.~* Patients who were willing to compliance with study and were available for follow up.~* Patients should be with good oral hygiene and without any acute illness~Exclusion Criteria:~* Patients with medical condition that prevent any surgical intervention such as patient with recent myocardial infarction, bleeding disorders, psychiatric problem and patients with pacemaker, uncontrolled systemic disease, immunocompromised patient and patients taking corticosteroid and anti-inflammatory drugs.~* Patients with history of head and neck radiotherapy.~* Pregnant or lactation women~* Active advanced uncontrolled periodontal disease and bad oral hygiene, or patients with local acute infection in relation to third molar especially pericoronitis.~* Patients who suffer from photodermatoses and photosensitized patients (photoallergies).~* Hyperthyroidism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: t

Study Arms:
- LLLT and ozone group (Type: EXPERIMENTAL): administered of low level laser therapy and ozone gel after extraction of impacted mandibular third molar
- LLLT group (Type: EXPERIMENTAL): administered of low level laser therapy after extraction of impacted mandibular third molar
- ozone group (Type: EXPERIMENTAL): administered of low ozone gel after extraction of impacted mandibular third molar
- control group (Type: NO_INTERVENTION): routinely extraction of impacted mandibular third molar

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for community-based OUD treatment centers (n = 30):~* prescribes FDA-approved medication to treat adult patients with OUDs~* enrolls 5+ new patients per month~* has at least 2 staff who provide psychosocial support to OUD patients~Exclusion criteria:~• None~Inclusion criteria for CM Providers (n = 60-150, range of 2-5 per center):~* has been involved in providing psychosocial support to OUD patients on pharmacotherapy~* has an active caseload~* is willing to commit to 14 months of CM training and support~Exclusion criteria:~• None~Inclusion Criteria for CM Leaders (n = 30-60, range of 1-2 per center):~* is responsible for supervising frontline CM Staff~* is willing to commit to 14 months of external leadership coaching~Exclusion criteria:~• None~Inclusion criteria for patients (n = 750):~* adult patients~* newly admitted to the opioid treatment center within the past 30 days~* prescribed any FDA-approved OUD medication~Exclusion criteria:~• issues that could interfere with the ability to complete a brief intake interview including acute intoxication, acute psychosis, acute mania, or cognitive impairment (prohibiting comprehension of the consent process), as reported by opioid treatment center staff or observed by research staff

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Addiction Technology Transfer Center (ATTC) Training (Type: ACTIVE_COMPARATOR): Half of the opioid treatment centers will receive the ATTC training strategy.
- Enhanced ATTC (E-ATTC) Training Strategy (Type: EXPERIMENTAL): Half of the opioid treatment centers will receive the E-ATTC training strategy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants will be 18 to 70 years of age~* Women may participate in the study, with the understanding that within the clinical population of fibromyalgia the there is a 7:1 ratio of female to male.~* Diagnosis of Fibromyalgia by 1990 ACR criteria (11/18 tender points)~* History of cervical or lumbar pain with fibromyalgia (this is expected in all patients since axial pain is required for diagnosis)~* Current stable treatment regimen for the last 4 weeks and projected stable treatment regimen for the next 2 months.~* English speaking~Exclusion Criteria:~* Current or history of cardiovascular, pulmonary, neurological, endocrine, or renal disease that would preclude the involvement in the study.~* TENS use in the last 5 years~* Pacemaker~* Uncontrolled blood pressure or diabetes~* Neuropathic pain condition~* Systemic autoimmune disorder (Lupus, PMR, RA, Psoriasis, Psoriatic arthritis)~* Spinal fusion - cervical or lumbar~* Metal implants in cervical or lumbar region~* Severe skin allergy to adhesive~* Allergy to nickel~* Pain level less than 4~* Pregnancy~* Epilepsy~* Change in or new drug or treatment program within the last month or in the next 2months, i.e. must have a stable treatment plan~* Unstable medical or psychiatric condition which in the opinion of the investigator could compromise the subject's welfare or confound the study results

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ActiveTENS (Type: ACTIVE_COMPARATOR): Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
- Placebo TENS (Type: PLACEBO_COMPARATOR): This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
- No TENS (Standard Care) (Type: NO_INTERVENTION): Participants will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Breakfast Rise, Education and Knowledge Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Children and young people aged between 5-17 years~* Diagnosis of type 1 diabetes for a minimum of one year~* On multiple daily injections (MDI) together with carbohydrate counting or Continuous Subcutaneous Insulin Infusion (CSII) using either open or closed loop systems.~* Use Dexcom continuous glucose monitoring (CGM) on a regular basis~* Have a Dexcom Clarity account and use the Clarity App~* Regularly eats a breakfast meal before midday~* Access to internet and email~Exclusion Criteria:~* Prescribed anti-hyperglycaemia agents i.e. Glucophage (Metformin) and or antidepressants.~* Any other medical conditions that may impact on the digestion and or absorption of nutrients, including coeliac disease and gastroparesis.~* Vegans~* Allergic or intolerant to the test meals~* Experiencing difficulties with food including diagnosed eating disorders~* Currently actively taking part in another research study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Test meal 1 (Type: OTHER): High glycaemic load breakfast meal
- Test meal 2 (Type: OTHER): High glycaemic lead with additional 10g protein breakfast meal
- Test meal 3 (Type: OTHER): Medium glycaemic load breakfast meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete